AB Science SA

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 4 2025 12:59:03 提供 Nasdaq GlobeNewswire

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 4 2025 12:02:30 提供 Nasdaq GlobeNewswire

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

04 3 2025 02:35:15 提供 Nasdaq GlobeNewswire

AB Science today provides an update on its masitinib platform

29 1 2025 13:03:14 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24 1 2025 12:01:01 提供 Nasdaq GlobeNewswire

AB Science will participate in the Biomed Forum investors conference

22 1 2025 12:59:47 提供 Nasdaq GlobeNewswire

AB Science provides a summary of the webcast held on December 16, 2024

17 12 2024 13:04:08 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

11 12 2024 12:06:34 提供 Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

28 10 2024 12:47:33 提供 Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

17 10 2024 13:28:54 提供 Nasdaq GlobeNewswire

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

10 10 2024 02:28:04 提供 Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2024 half-year financial report

30 9 2024 12:33:35 提供 Nasdaq GlobeNewswire

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

26 9 2024 02:28:30 提供 Nasdaq GlobeNewswire

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 9 2024 11:51:06 提供 Nasdaq GlobeNewswire

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

08 7 2024 01:56:02 提供 Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 6 2024 06:31:02 提供 Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 5 2024 10:30:34 提供 Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 5 2024 12:02:52 提供 Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2023 and provides an update on its activities

15 5 2024 14:16:47 提供 Nasdaq GlobeNewswire

AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13 5 2024 12:08:35 提供 Nasdaq GlobeNewswire